

Modulation of Hippocampal Acetylcholine Release: A Potent Central Action of Interleukin-2

Uwe-Karsten Hanisch, David Seto, and Rémi Quirion

Douglas Hospital Research Centre, Department of Psychiatry, and Department of Pharmacology and Therapeutics, McGill University, Montreal, Québec, H4H 1R3 Canada

The potential of the T-cell growth factor interleukin-2 (IL-2) to modulate the release of ACh from rat hippocampus was studied *in vitro*, as a means to investigate the possible functional significance of this cytokine in the CNS. Hippocampal slices were superfused with Krebs' buffer medium, and endogenous ACh released into the superfusate was measured using a radioenzymatic assay. Recombinant human IL-2 present during a stimulation with 25 mM KCl altered, in a concentration-dependent manner, the evoked transmitter release. At a concentration of 15 U/ml (≤ 1 nM), IL-2 inhibited ACh release by more than 50% of the control level (evoked ACh release from the untreated contralateral hemispheres). Inhibition was observed within 20 min of tissue exposure to IL-2 and lasted for up to 1 hr. The inhibitory effect of IL-2 was reversible since transient tissue exposure to IL-2 did not affect subsequent evoked ACh release. IL-2 at this concentration also significantly decreased evoked ACh in frontal cortical slices, but was ineffective in the parietal cortex and striatum, revealing that IL-2 selectively modulates the release of ACh from certain, but not all, cholinergic nerve terminals in the CNS. At very low concentrations (1.5 μ M/ml, ≤ 0.1 pM), IL-2 transiently increased hippocampal evoked ACh release, resulting in a biphasic dose-response profile with no significant effect observed at 0.015 μ M/ml (≤ 1 fM). Other cytokines (IL-1 α , IL-3, IL-5, IL-6, interferon α), tested in hippocampal slice incubations, failed to modulate ACh release. These results suggest that the immunoregulator IL-2 is a potent and selective modulator of ACh release in selected regions of the rat brain, an effect apparently not shared with other cytokines. The potent action of IL-2 on ACh release most likely relates to the discrete distribution of IL-2(-like) antigen and 125 I-IL-2 binding sites in rat brain tissues (Lapchak et al., 1991).

[Key words: interleukin-2, cytokines, neuromodulation, transmitter release, ACh, hippocampus]

Cytokines are signaling peptides of the immune system. Interleukin-2 (IL-2) was one of the first cytokines to be characterized in detail (for a review, see Hatakeyama and Taniguchi, 1991). IL-2 is predominantly synthesized by antigen- or mito-

gen-activated T-cells and regulates, as an autocrine/paracrine growth hormone, their clonal expansion. IL-2, in conjunction with antigen, mitogen, or anti-immunoglobulin antibodies, also controls B-cell proliferation and differentiation into antibody-secreting cells. Furthermore, by acting on cytolytic T-lymphocytes, and natural killer (NK) and lymphokine-activated killer cells, IL-2 participates in the activation of cytotoxic immune responses. These diverse immunoregulatory functions are mediated by specific interactions with cell membrane IL-2 receptors (IL-2R), which are composed of two moieties, IL-2R α /p55/Tac and IL-2R β /p70, respectively (Kuziel and Greene, 1990; Waldmann, 1991). IL-2R α and IL-2R β bind IL-2 with low ($k_D \approx 10^{-8}$ M) and moderate ($k_D \approx 10^{-9}$ M) affinity; upon activation-induced association to the noncovalent $\alpha\beta$ -heterodimer they form the high-affinity IL-2 receptor complex ($k_D \approx 10^{-11}$ M). Other putative components of the receptor/effector complex are predicted that may control ligand binding and receptor-mediated IL-2 endocytosis, in addition to enzymatic activities involved in IL-2-triggered signal transduction(s). Because of its potent immunostimulatory properties, IL-2 has been introduced as an anti-tumor drug (for review, see Rosenberg, 1990) and is now clinically used in various immunotherapeutic strategies.

IL-2, among other cytokines, may also act as a neuromodulator in the CNS. Regulatory functions in the nervous tissue have been proposed, for example, for the growth and differentiation of glial and neuronal cells as well as for the control of neuronal activity in the hippocampus, locus coeruleus, and certain hypothalamic nuclei (for a review, see Merrill, 1990, 1991; Nisticò and De Sarro, 1991; Plata-Salamán, 1991). As a modulator of the neuroendocrine system, IL-2 can directly alter the release of pituitary hormones (Karanth and McCann, 1991). The presence of biological activities as well as IL-2(-like) immunoreactive material (IRM), IL-2R-associated IRM, IL-2 mRNA, and 125 I-IL-2 binding sites has been demonstrated in the rodent and, partly, in the human brain, under normal and pathophysiological conditions (Nieta-Sampedro and Chandry, 1987; Luber-Narod and Rogers, 1988; Araujo et al., 1989; Merrill, 1990; Lapchak et al., 1991; Villemain et al., 1991). Moreover, IL-2-induced disruption and penetration of the blood-brain barrier has been subject to experimental studies and clinical observation (Ellison et al., 1987, 1990; Saris et al., 1988; Alexander et al., 1989; Watts et al., 1989; Banks et al., 1991; Ellison and Merchant, 1991). It thus appears that effects of IL-2 in the brain could be due to the genuine existence of IL-2(-like) peptides intrinsic to the CNS, or to elevated blood-borne IL-2.

Elevated amounts of peripheral IL-2 in patients undergoing high-dose IL-2 immunotherapy are reflected by IL-2 concentrations in the cerebrospinal fluid reaching up to 9 U/ml (Saris

Received Sept. 30, 1992; revised Jan. 15, 1993; accepted Feb. 4, 1993.

This work was supported by the Medical Research Council of Canada and by the Fonds de Recherche en Santé du Québec (FRSQ). U.-K.H. is a recipient of a fellowship of the Human Frontier Science Program. D.S. and R.Q. are holders of studentship and Chercheur-Boursier awards from the FRSQ, respectively.

Correspondence should be addressed to Dr. Rémi Quirion, Douglas Hospital Research Centre, Lehmann Pavillon, 6875 Boulevard Lasalle, Montréal, Québec H4H 1R3, Canada.

Copyright © 1993 Society for Neuroscience 0270-6474/93/133368-07\$05.00/0

et al., 1988). At these concentrations, IL-2 immunotherapy is accompanied by a variety of side effects, including adverse neurologic symptoms such as memory impairments (Denicoff et al., 1987; Plata-Salamán, 1991). The hippocampus, a brain structure enriched with IL-2/IL-2R IRM, ¹²⁵I-IL-2 binding sites (Lapchak et al., 1991), and IL-2 mRNA (Villemain et al., 1991), is most probably involved in certain aspects of memory and therefore one of the likely targets of CNS-directed IL-2 activities. Of the various neurotransmitters present in the hippocampal formation, ACh is the candidate that has most often been related to learning and memory.

The objective of the present study was thus to investigate the potential of IL-2 to modulate ACh release in the rat hippocampal formation using *in vitro* brain slice superfusion. The results indicate that IL-2 is able to modify in a concentration-dependent manner ACh release in the hippocampus. Its minimal effective dose being in the (sub)picomolar range, it demonstrates that IL-2 is one of the most potent modulators of ACh release characterized so far. This effect seems to be specific, since various other cytokines tested failed to alter ACh release.

Parts of the results have recently been presented in abstract form (Seto et al., 1991).

Materials and Methods

Male albino Sprague-Dawley rats (300–325 gm) were obtained from Charles River (breeding colony St. Constant, Quebec, Canada). Recombinant human IL-2 (rhIL-2), frequently shown to be effective in the rat CNS (see Karanth and McCann, 1991), was from Sigma Chemical Co. (catalog number T-3267; St. Louis, MO). Interferon α (rhIFN α) was from Janssen/Cedarlane Laboratories (Hornby, Ontario, Canada). All other cytokines, in the human recombinant form (IL-1 α , IL-3, IL-5, and IL-6), were obtained from Upstate Biotechnology (Lake Placid, NY). Adenosine triphosphate (ATP), dithiothreitol, and bovine serum albumin (BSA) were from Boehringer Mannheim (Laval, Quebec, Canada); choline kinase (ATP:choline phosphotransferase, EC 2.7.1.32), acetylcholinesterase type V-S (acetylcholine hydrolase, EC 3.1.1.7), acetylcholine chloride, physostigmine sulfate, and Amberlite CG-400 (chloride form) were from Sigma Chemical Co. (St. Louis, MO); tetraphenylboron and butyronitrile were from Aldrich Chemical Co. (Milwaukee, WI); γ -³²P-ATP (2–10 mCi/mmol) was from New England Nuclear (Mississauga, Ontario, Canada); Ecolite was from ICN (Montreal, Quebec, Canada). All other chemicals were of analytical grade and purchased from Fisher Scientific (Montreal, Quebec, Canada).

Tissue preparation and release studies. Rats were decapitated and the brains were removed into chilled Krebs' buffer medium (KBM) composed of (in mM) NaCl, 120; KCl, 4.6; CaCl₂, 2.4; KH₂PO₄, 1.2; MgSO₄, 1.2; D-glucose, 9.9; NaHCO₃, 25; saturated with O₂/CO₂ (95%:5%), and adjusted to pH 7.4. Tissue regions (hippocampus, striatum, frontal, or parietal cortex) were rapidly dissected on ice and sliced at 400 μ m intervals with a McIlwain tissue chopper. Slices of one hemisphere were immediately placed in a superfusion chamber, built according to Richter (1976), and superfused at a rate of 0.5 ml/min with KBM containing choline chloride (10 μ M), to support synthesis of ACh, and physostigmine (30 μ M for the hemisulfate), to prevent enzymatic degradation of ACh. The buffer reservoir was continuously bubbled with O₂/CO₂ (95%:5%) mixture. The temperature of the chambers and the medium was kept at 37°C. After 45 min, superfusate fractions (10 or 20 min each) were collected. Aliquots were spun in a microcentrifuge (Biofuge B 13, Heareus, 13,000 rpm, 3 min), and 1.3 ml of the supernatant was stored at -70°C until further processing. Tissue slices were stimulated with KBM containing 25 mM KCl (K⁺ KBM), with equimolar reduction in NaCl, in the presence of IL-2. Controls were stimulated in parallel with K⁺ KBM omitting the interleukin. At the end of the superfusion, tissue slices were removed from the chambers and protein content was measured in triplicate according to Lowry et al. (1951), using BSA dissolved in KBM as a standard.

Evoked release of ACh from hippocampal slices was also determined in tissue incubations carried out according to Araujo et al. (1989). Briefly, hippocampal slices (300 μ m) were incubated at 37°C in KBM (1 ml) for 70 min, with changes of the medium after 30 and 60 min. Subse-

quently, slices of one hemisphere were incubated in 1.35 ml of KBM containing BSA (1 mg/ml) and one of the following cytokines: IL-1 α , IL-3, IL-5, IL-6, or IFN α . After 20 min, the slices were incubated for another 20 min with the cytokine dissolved in K⁺ KBM containing BSA (1 mg/ml). As controls, slices from the contralateral hemisphere were treated in parallel, but in the absence of the cytokine. Supernatants and tissues were separated by centrifugation and treated as described for the superfusions.

Determination of ACh. ACh was determined using a radioenzymatic assay (Goldberg and McCaman, 1973). Briefly, ACh was extracted from samples by mixing an aliquot of 400 μ l with an equal volume of tetraphenylboron in butyronitrile (10 gm/liter). Separation of the phases was completed by centrifugation (Biofuge B 13, Heareus, 13,000 rpm, 4 min); 300 μ l of the organic phase was removed and shaken (4 min) with a half-volume of AgNO₃ solution (20 gm/liter). The mixture was spun (Biofuge B 13, Heareus, 13,000 rpm, 4 min), and 110 μ l of the aqueous phase was placed in a new tube containing 10 μ l MgCl₂ solution (1 M). After shaking and spinning, 100 μ l of the supernatant was transferred into a glass tube and evaporated. The pellet was dissolved in 32 μ l of a reaction mixture composed of choline kinase (0.005 U), ATP (0.8 mM), MgCl₂ (12.5 mM), and dithiothreitol (5 mM) in glycylglycine buffer (25 mM, pH 8.0). Following 30 min of incubation at 30°C, 10 μ l of ³²P-ATP solution (0.45 μ Ci) containing acetylcholinesterase (2 U) was added to the sample. The mixture was incubated for another 30 min at 30°C. The reactions were terminated by addition of 100 μ l NaOH (50 mM). As a result, only the choline derived from ACh was ³²P-phosphorylated. The samples were placed on glass pipette columns filled with Amberlite CG-400 (approximately 800 μ l bed volume) that was converted to its formate form and equilibrated with NaOH (50 mM). The columns were rinsed with 3 ml of NaOH (50 mM) to elute any phosphocholine, while excessive ³²P-ATP (accounting for more than 99% of the activity added) was retained on the column. The eluate, collected in scintillation vials, was mixed with scintillation cocktail, and radioactivity was measured by liquid scintillation spectrometry. Standards of ACh chloride (0–400 pmol in 400 μ l of KBM) were processed in parallel. All determinations were carried out in triplicate.

Calculations and statistics. Concentrations given for IL-2 on the basis of biological activity refer to BRMP units. Approximate molar concentrations were calculated from the specific activity. Evoked transmitter release during superfusions was expressed as pmol ACh/min/mg protein and regarded as the net transmitter release over basal efflux. The basal efflux was determined from the superfusate samples collected prior, between, as well as following periods of K⁺ stimulations, respectively, depending on the experimental paradigm. To calculate the evoked release during a depolarization, the baseline was estimated for this period, and the values obtained for the basal efflux were subtracted from the total amount of ACh found in the superfusate. Statistical evaluations were carried out using the program ncss (parallel or paired, two-tailed) *t* test, respectively, following *F* test, *P* < 0.05 being considered significant.

Results

Stimulation of ACh release from brain slices was carried out with 25 mM KCl, increasing the total concentration of K⁺ in the medium from 5.8 to 26.2 mM. At this concentration, evoked release is known to be at submaximal level (Lipton, 1985; Pearce et al., 1991). Submaximal stimulation was regarded appropriate to reveal both drug-dependent attenuation as well as augmentation of the evoked transmitter release. Figure 1 shows the hippocampal release profile for endogenous ACh as determined for a stimulation period of 60 min. The average basal release was 0.98 \pm 0.29 pmol/min/mg protein (mean \pm SEM, *n* = 98). The average decline of the baseline value was determined to be 1.1%/hr (*n* = 18), demonstrating the stability and viability of the tissue preparations under the present incubating conditions.

Effects of IL-2 on hippocampal ACh release

The effect of IL-2 on the evoked hippocampal ACh release is displayed in Table 1 for various times of tissue exposure to the interleukin. Hippocampal slices were first superfused with normal KBM for 60 min to establish the basal release. Subsequent-




Figure 1. K^+ -evoked hippocampal ACh release using *in vitro* slice superfusion. Slices were superfused with normal KBM and then stimulated for 60 min with KBM containing 25 mM KCl (K^+). Data represent the mean \pm SEM of 36 superfusions.

ly, the tissue was stimulated for up to 60 min with K^+ KBM containing various concentrations of IL-2. The ACh release in the presence of IL-2 was compared to controls that were stimulated in the absence of IL-2.

Figure 2 represents an overlay of the concentration–response relations obtained from the various intervals of tissue stimulation, revealing the time dependency of the IL-2-mediated effects. The augmentation of ACh release by IL-2 at 1.5 mU/ml was obvious during the early period of stimulation and attenuated rapidly with time. On the contrary, the inhibition of ACh release by 15 U/ml IL-2 was a consistent finding even over a prolonged period of stimulation. Only tendencies toward decreased or increased values were found for 150 and 0.015 mU/ml of IL-2.

During the first 20 min of K^+ stimulation, evoked ACh release was modulated by IL-2 in a concentration-dependent manner. At 15 U/ml, IL-2 inhibited ACh release by more than 50% of the control value. At a 100-fold lower concentration (150 mU/ml), ACh release was only nonsignificantly attenuated (Fig. 2). However, when the concentration of IL-2 was further lowered to 1.5 mU/ml, an increase in the amount of ACh released by a 20 min K^+ KBM exposure was detected (Fig. 2). No significant




Figure 2. Effects of IL-2 on the evoked release of ACh from hippocampal slices. The dose–response curves were obtained from three intervals during tissue stimulation with 25 mM KCl (\square , 0–20 min; \circ , 20–40 min; \triangle , 40–60 min). Data are expressed as percentage of control measurements carried out in the absence of IL-2. For clarity, error bars were omitted, but values are given in Table 1. *, $P < 0.05$.

change was observed for the tissue samples treated with 0.015 mU/ml IL-2.

During the subsequent period of stimulation, that is, the interval between 20 and 40 min, there was still a marked decrease in the evoked ACh release from slices exposed to 15 U/ml IL-2 (Fig. 2). With lowering the concentration of IL-2, ACh release returned to control levels. There was no longer a significant increase of evoked transmitter release for IL-2 at 1.5 mU/ml.

An inhibitory effect of IL-2 was also detected during the interval between 40 and 60 min of continuous superfusion with K^+ KBM (Fig. 2). Almost 40% reduction in ACh release was found for chambers superfused with 15 U/ml IL-2. However, the IL-2 effect was significantly weaker, when compared to the period before, that is, the interval between 20 and 40 min ($P < 0.05$ in a paired t test) (Fig. 2). Calculated for the total stimulation period of 60 min, the overall evoked release was (percentage of control) 115.4, 121.9, 80.3, and 48.5 for the experimental groups treated with 0.015 mU/ml, 1.5 mU/ml, 150 mU/ml, and 15 U/ml IL-2, respectively.

IL-2 also inhibited ACh release when added to an ongoing stimulation. As shown in Figure 3, IL-2 at 15 U/ml transiently decreased the evoked ACh release when it was added to stimulated hippocampal slices. The profile returned to control levels after 40 min of IL-2 presence, equivalent to 70 min of continuous stimulation.

Reversal of the IL-2-mediated inhibition of ACh release

When hippocampal slices were stimulated with K^+ KBM for a first period of 30 min (S_1) and, following a 30 min rinsing with normal KBM, were stimulated a second time (S_2 , 30 min), the amounts of ACh released by S_1 and S_2 were identical (1.04 for the ratio $S_2:S_1$). To test whether the presence of IL-2 during S_1 would alter subsequent ACh release during S_2 , in the absence of IL-2, hippocampal slices were exposed to 150 U/ml IL-2 for 30 min and rinsed for 30 min, before being restimulated. The profiles in Figure 4 show that transient presence of IL-2 did not alter the efficacy of later stimulations. Consequently, toxic or permanent effects of IL-2 on the tissue could be excluded for the duration of the experiments.

Table 1. Effect of IL-2 on the evoked release of endogenous ACh from hippocampal slices during superfusion

Time (min)	IL-2 (mU/ml)			
	0.015	1.5	150	15,000
0–20	122.2 \pm 11.5 (n = 10)	145.9 \pm 26.4 (n = 7)*	77.1 \pm 8.3 (n = 9)	44.8 \pm 15.6 (n = 10)*
20–40	115.1 \pm 15.4 (n = 10)	123.2 \pm 7.0 (n = 8)	87.8 \pm 9.1 (n = 9)	38.6 \pm 10.8 (n = 10)*
40–60	108.8 \pm 10.1 (n = 10)	96.5 \pm 16.2 (n = 8)	75.9 \pm 8.7 (n = 9)	62.0 \pm 12.5 (n = 8)*

Data are evoked hippocampal ACh release, expressed as percentage of control, determined for various periods of tissue exposure to IL-2 in the presence of 25 mM KCl. Release over basal efflux was determined as pmol ACh/min/mg protein. Data for slices treated with IL-2 were converted to percentage of the average release evoked from control slices. The data for a given concentration represent the mean \pm SEM (n) of two experiments.

* $P < 0.05$.




Figure 3. Effect of IL-2 on an ongoing stimulation of evoked ACh release from hippocampal slices. The tissue was stimulated with 25 mM KCl for a total period of 90 min (K^+); 30 min after the onset of the stimulation IL-2 (15 U/ml) was added to the superfusion medium (arrowhead). Data are given as percentage (mean \pm SEM, $n = 5$) of untreated controls. *, $P < 0.05$.

Regional differences in the effect of IL-2

Besides the hippocampal formation, IL-2 and IL-2R-associated IRM has been localized in a variety of rat brain regions, including the neostriatum and the cerebral cortex (Araujo et al., 1989; Lapchak et al., 1991). To test whether IL-2 could also modulate evoked ACh release in those regions, slices of striatum as well as of frontal and parietal cortices were superfused and K^+ stimulated over 60 min in the absence (controls) or presence of IL-2. The results are summarized in Figure 5. The average basal release was (in pmol/min/mg protein) 5.94 ± 0.84 ($n = 32$), 2.56 ± 0.48 ($n = 27$), and 3.27 ± 0.64 ($n = 21$) for the striatum, frontal, and parietal cortices, respectively.

IL-2 at 15 U/ml did not affect evoked ACh release in striatal tissue (Fig. 5A). The release in the presence of IL-2 was in the range between $82.1 \pm 12.2\%$ and $126.0 \pm 20.2\%$ when compared to the corresponding control values. Neither was there any effect of IL-2 on slices from parietal cortex; evoked ACh was between $90.2 \pm 16.6\%$ and $98.5 \pm 13.3\%$ of the corresponding control level (Fig. 5C). However, 15 U/ml IL-2 reduced the evoked ACh release from frontal cortex during the first 20 min of K^+ stimulation (Fig. 5B). The evoked release during this period was determined to be $49.8 \pm 9.9\%$ ($n = 5$) of the control value.

As was shown for the hippocampus, preexposure to IL-2 did not modify the subsequent release pattern in any of these other tissues (insets in Fig. 5A–C). There was thus no evidence for an altered transmitter release as a consequence of a previous incubation of the tissues with IL-2. The striatal evoked ACh release during S_2 (Fig. 5A) was 85.7% of the control amount, and 108.5% in a second experiment. When compared to the corresponding controls, ACh releases over baseline were 114.0% and 93.7% for the S_2 periods in the frontal and parietal cortices, respectively.

Effects of other cytokines

The specificity of the IL-2 effect on hippocampal ACh release was determined in slice incubations as described in Araujo et al. (1989), in the presence or absence (control) of several other




Figure 4. Evoked hippocampal ACh release following a transient exposure of the tissue to IL-2. Slices were stimulated for a first period of 30 min (S_1 , $n = 11$) with 25 mM KCl, rinsed for 30 min, and stimulated a second time for 30 min (S_2). Controls showed identical amounts of released ACh for S_1 and S_2 (left). Another group of tissue samples ($n = 6$) was exposed to IL-2 (150 U/ml) during S_1 . Following rinsing, the tissue was stimulated in the absence of IL-2 (S_2 shown in the right). From the left to the right, the peak areas (corresponding to the amounts of released transmitter) were calculated to be 100.0%, 104.4%, and 102.8%. Data are given as mean \pm SEM.

cytokines. As shown in Table 2, IFN α , IL-1 α , IL-3, IL-5, and IL-6 did not significantly alter ACh release in this tissue. In preliminary experiments, we also observed that rat IL-2, the peptide homologous to human IL-2, modulated ACh release at 50 U/ml.

Discussion

The results point to a neuromodulatory action of IL-2 on certain populations of cholinergic neurons. At a higher concentration (15 U/ml, ≤ 1 nM), IL-2 showed a pronounced inhibition of evoked ACh release in the hippocampus and frontal cortex, while being ineffective in the striatum and parietal cortex. Interestingly, a lower concentration of IL-2 (1.5 mU/ml, ≤ 0.1 pM) stimulated ACh release in the hippocampal formation. It is thus evident that the effect of this cytokine on ACh release is (1) concentration dependent and (2) region specific, with terminals of selected cholinergic projections (but not striatal intrinsic neurons) being sensitive to its modulatory activity.

Modulation of ACh release has been reported for various agents, including muscarinic agonists and antagonists (Raiteri et al., 1984; Lapchak et al., 1989), excitatory amino acids (Scatton and Lehmann, 1982), neurotensin (Lapchak et al., 1990), and somatostatin (Araujo et al., 1990). However, micromolar concentrations of these agents are required to produce significant effects while IL-2 is effective at markedly lower concentrations (≤ 0.1 pM) that most likely have physiological relevance. Similarly, sympathetic neurite outgrowth is optimally enhanced by 0.2–2 U/ml IL-2 (Haugen and Letourneau, 1990) while neuroendocrine effects of IL-2 were detected using picomolar to femtomolar concentrations (Karanth and McCann, 1991). IL-2, in picomolar quantities, is also known to produce soporific effects and to modulate EEG spectrum (Nisticò and De Sarro, 1991). Higher concentrations (200 to ≥ 3000 U/ml) were required to block long-term potentiation (LTP) in the rat hippocampus (Tancredi et al., 1990).

For the duration of our experiments potential neurotoxic ef-




Figure 5. Effects of IL-2 on the evoked ACh release from slices of the striatum (*A*, $n = 5$), frontal cortex (*B*, $n = 5$), and parietal cortex (*C*, $n = 6$). Tissue slices were stimulated with KBM containing 25 mM KCl in the presence (○) or absence (□) of 15 U/ml IL-2. The insets in *A–C* represent the release profiles obtained with 30 min of KCl stimulation from controls (□) and from slices following to an exposure to IL-2 (150 U/ml, ○). Axis dimensions in the insets are the same as in the full-size graphs. For further explanation see Results. All data are given as mean \pm SEM. *, $P < 0.05$.

Table 2. K^+ -evoked ACh release from hippocampal slices incubated in the presence of various cytokines

	Hippocampal ACh release (% of control)
IFN α (5 nM)	99.8 \pm 23.7 ($n = 7$)
IL-1 α (1 nM)	93.3 \pm 8.2 ($n = 8$)
IL-3 (5 nM)	101.9 \pm 5.3 ($n = 10$)
IL-5 (1.3 nM)	93.5 \pm 4.0 ($n = 10$)
IL-6 (5 nM)	95.1 \pm 6.5 ($n = 10$)

Total ACh release during a stimulation of 20 min with 25 mM KCl was determined and expressed as percentage of the transmitter release from the corresponding controls (untreated contralateral hemispheres). The overall control value was 5.95 \pm 0.27 pmol/min/mg protein ($n = 44$). Data are given as mean \pm SEM.

fects of IL-2 were not observed, but have been documented in neuronal cell culture following a 24 hr exposure to IL-2 (Araujo and Cotman, 1991). In the present series of experiments, subsequent ACh release during K^+ stimulation was not altered by previous exposure to IL-2. Furthermore, over prolonged periods of stimulation in the presence of IL-2, inhibition of hippocampal evoked ACh release attenuated, being significantly less pronounced or absent after 40 min. In the IL-2R α /IL-2R β receptor complex, the α -subunit determines the fast association with IL-2 ($t_{1/2} = 37$ sec), whereas the β -subunit contributes to the slow dissociation of the ligand ($t_{1/2} = 285$ min) and to signal transduction (Kuziel and Greene, 1990; Waldmann, 1991). Similar kinetics likely apply in the CNS, the putative K_D value (25 μ M) of 125 I-IL-2 binding sites (Araujo et al., 1989) being very low, rendering rapid dissociation ("washout") most unlikely. Taken all together, this suggests the termination of the IL-2 signaling by endocytosis of the ligand/receptor complex (Legrue et al., 1991). As shown in YT^+ cells, 125 I-IL-2 is almost completely internalized after 30–40 min incubation period (Fung et al., 1988).

While IL-2 was shown to be a very potent modulator of hippocampal ACh release, several other cytokines with established CNS activities (Plata-Salamán, 1991), that is, IFN α , IL-1 α , IL-3, IL-5, IL-6 (in the present study), and IL-1 β , as well as IL-4 (in Araujo et al., 1989), were ineffective, indicating that ACh release in the hippocampus is sensitive to a specific effect of IL-2 that is not shared by other well-known cytokines.

IL-2(-like) and IL-2R-associated (Tac antigen-like) IRM are present in the rat hippocampal formation, especially in the stratum pyramidale of the hippocampus proper as well as in the granule cell layer of the dentate gyrus (Lapchak et al., 1991). It is well known that cholinergic septal projections terminate throughout the hippocampal region, but most heavily in the strata oriens and radiatum of subfields CA2 and CA3, as well as in the infra- and supragranular zones of the dentate gyrus, making contacts with pyramidal and granule cell bodies and dendrites (Semba and Fibiger, 1989). The proximity of IL-2-related IRMs and cholinergic terminals is very striking and may thus explain our functional observation, that is, the modulation of ACh release by the cytokine in the hippocampal formation. On the other hand, IL-2/IL-2R-like IRM in the frontoparietal cortex concentrates within layer IV, with the staining decreasing in more caudal and ventral cortical areas (Lapchak et al., 1991). In the rat, cholinergic fibers innervating the frontoparietal cortex originate from cells in the vicinity of the substantia innominata and the ventromedial globus pallidus (Semba and Fibiger, 1989). Although some intrinsic ACh neurons exist in the cortex (layers

II/III), the laminar pattern of cholinergic terminals predominantly arises from these projections, with high densities seen in layer V, and to a lesser extent in layer IV. It thus appears that most prominent effects of IL-2 on ACh release were observed in cortical and hippocampal areas that contain cholinergic projection terminals in proximity to IL-2/IL-2R IRM.

In contrast, IL-2 failed to modulate ACh release in the striatum, an area enriched with ACh interneurons (1–2% of the cells; Semba and Fibiger, 1989) and detectable quantities of IL-2/IL-2R IRM (Lapchak et al., 1991). This illustrates that IL-2 is not a universal modulator of ACh release, but exerts its effects in regions where IL-2-related IRM was localized in vicinity to the terminals of far-projecting ACh neurons.

The modulatory effect of IL-2 on ACh release, especially in the hippocampus, is of potential interest in regard to the impairments of cholinergic functions in Alzheimer's disease (AD) (Whitehouse et al., 1982; Quirion et al., 1990). In that context, it is intriguing that cholinergic neurons of the striatum, an area usually spared in AD, are insensitive to IL-2. It is also known that various markers of the immune system, such as major histocompatibility complex glycoproteins, immunoglobulin, complement, and cytokine receptors, infiltrating T-cells, cytokines, and complement factors, associated with neurodegenerative plaques and neurofibrillary tangles, are present in AD brains, implicating immune-mediated autodestruction as an important pathological event in this disorder (McGeer and Rogers, 1992). IL-2, though not being the sole candidate, could play a crucial role in the central cascading of immune-related markers, as it does in the periphery.

Regarding the biphasic profile of action observed in the hippocampus, IL-2, normally expressed in low amounts, could usually stimulate ACh release. However, under pathological conditions, levels of IL-2 are likely increased (McGeer and Rogers, 1992) and could conceivably contribute to decreased levels of ACh released by terminals especially in the regions primarily affected in AD, such as the hippocampus and the frontal cortex. High concentrations of IL-2 are known to interfere with LTP in the hippocampus (Tancredi et al., 1990), an observation that could also relate to neurologic side effects associated with high-dose IL-2 immunotherapies (Denicoff et al., 1987; Plata-Salamán, 1991).

Bidirectional communication between the immune system and the CNS is likely mediated by both direct cellular contacts, for example, via innervation of immunocompetent organs, and soluble factors triggering effects in remote tissues or providing humoral feedbacks (Bateman et al., 1989; De Micco, 1989; Dunn, 1989; Jankovic, 1989; Rabin et al., 1989; Sternberg, 1989; Merrill, 1990; Plata-Salamán, 1991). Some of these mediators can be produced by cells of both systems, obliterating the "classical" demarcation between immuno- and neuroregulators. Immunoregulators likely play pivotal roles in normal CNS development and function, in the induction and coordination of post-traumatic events (Plata-Salamán, 1991; Hall and Rao, 1992), and probably in pathogenetic processes associated with neurologic disorders (Blume and Vitek, 1989; Matsuyama et al., 1991; Vandenabeele and Fiers, 1991; McGeer and Rogers, 1992; Royston et al., 1992). Upon challenge of an immune or inflammatory response or during cytokine-based immunotherapy, cytokines may become more active in the CNS, provided that they have access to functionally coupled receptors in the brain. In the case of IL-2, evidence has been reported that fulfills these predictions. However, it remains to be shown whether other

factors known to be induced by IL-2, such as tumor necrosis factor, are partly responsible for effects ascribed to IL-2 (Ellison and Merchant, 1991). It is thus of great interest to determine whether the modulatory action of this cytokine on cholinergic nerve terminals is due to a direct effect or whether it involves other mediators.

References

- Alexander JT, Saris SC, Oldfield EH (1989) The effect of interleukin-2 on the blood-brain barrier in the 9L gliosarcoma rat model. *J Neurosurg* 70:92–96.
- Araujo DM, Cotman CW (1991) Effects of lymphokines on glial and neuronal cells *in vitro*: a role for lymphokines as modulators of neural-glial interactions. *Soc Neurosci Abstr* 17:475.19.
- Araujo DM, Lapchak PA, Collier B, Quirion R (1989) Localization of interleukin-2 immunoreactivity and interleukin-2 receptors in the rat brain: interaction with the cholinergic system. *Brain Res* 498:257–266.
- Araujo DM, Lapchak PA, Collier B, Quirion R (1990) Evidence that somatostatin enhances endogenous acetylcholine release in the hippocampus. *J Neurochem* 55:1546–1555.
- Banks WA, Ortiz L, Plotkin SR, Kastin AJ (1991) Human interleukin (IL) 1 α , murine IL-1 α and murine IL-1 β are transported from blood to brain in the mouse by a shared saturable mechanism. *J Pharmacol Exp Ther* 259:988–996.
- Bateman A, Singh A, Kral T, Solomon S (1989) The immune-hypothalamic-pituitary-adrenal axis. *Endocr Rev* 10:92–112.
- Blume AJ, Vitek MP (1989) Focusing on IL-1-promotion of β -amyloid precursor protein synthesis as an early event in Alzheimer's disease. *Neurobiol Aging* 10:406–408.
- De Micco C (1989) Immunology of central nervous system tumors. *J Neuroimmunol* 25:93–108.
- Denicoff KD, Rubinow DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosenstein D, Rosenberg DA (1987) The neuropsychiatric effects of treatment with interleukin-2 and lymphokine activated killer cells. *Ann Intern Med* 107:293–300.
- Dunn AJ (1989) Psychoneuroimmunology for the psychoneuroendocrinologist: a review of animal studies of nervous system-immune system interactions. *Psychoneuroendocrinology* 14:251–274.
- Ellison MD, Merchant RE (1991) Appearance of cytokine-associated central nervous system myelin damage coincides temporally with serum tumor necrosis factor induction after recombinant interleukin-2 infusion in rats. *J Neuroimmunol* 33:245–251.
- Ellison MD, Povlishock JT, Merchant RE (1987) Blood-brain barrier dysfunction in cats following recombinant interleukin-2 infusion. *Cancer Res* 47:5765–5770.
- Ellison MD, Krieg RJ, Povlishock JT (1990) Differential central nervous system responses following single and multiple recombinant interleukin-2 infusions. *J Neuroimmunol* 28:249–260.
- Fung MR, Ju G, Greene WC (1988) Co-internalization of the p55 and p70 subunits of the high-affinity human interleukin 2 receptor: evidence for a stable ternary receptor complex. *J Exp Med* 168:1923–1928.
- Goldberg AM, McCaman RE (1973) The determination of picomole amounts of acetylcholine in mammalian brain. *J Neurochem* 20:1–8.
- Hall AK, Rao MS (1992) Cytokines and neurokines: related ligands and related receptors. *Trends Neurosci* 15:35–37.
- Hatekayama M, Taniguchi T (1991) Interleukin-2. In: *Peptide growth factors and their receptors*, Vol 1 (Sporn MB, Roberts AB, eds), pp 523–540. New York: Springer.
- Haugen PK, Letourneau PC (1990) Interleukin-2 enhances chick and rat sympathetic, but not sensory, neurite outgrowth. *J Neurosci Res* 25:443–452.
- Jankovic BD (1989) Neuroimmunomodulation: facts and dilemmas. *Immunol Lett* 21:101–118.
- Karanth S, McCann SM (1991) Anterior pituitary hormone control by interleukin 2. *Proc Natl Acad Sci USA* 88:2961–2965.
- Kuziel WA, Greene WC (1990) Interleukin-2 and the IL-2 receptor: new insights into structure and function. *J Invest Dermatol* 94:27S–32S.
- Lapchak PA, Araujo DM, Quirion R, Collier B (1989) Binding sites for [3 H]AF-DX 116 and effect of AF-DX 116 on endogenous acetylcholine release from rat brain slices. *Brain Res* 496:285–294.

- Lapchak PA, Araujo DM, Quirion R, Beaudet A (1990) Neurotensin regulation of endogenous acetylcholine release from rat cerebral cortex: effect of quinolinic acid lesions of the basal forebrain. *J Neurochem* 55:1397–1403.
- Lapchak PA, Araujo DM, Quirion R, Beaudet A (1991) Immunoradiographic localization of interleukin 2-like immunoreactivity and interleukin 2 receptors (Tac antigen-like immunoreactivity) in the rat brain. *Neuroscience* 44:173–184.
- Legrue SJ, Sheu TL, Chernajovsky Y (1991) The role of receptor-ligand endocytosis and degradation in interleukin-2 signaling and T-lymphocyte proliferation. *Lymphokine Cytokine Res* 10:431–436.
- Lipton P (1985) Brain slices. In: *General neurochemical techniques, neuromethods, Ser 1, Neurochemistry* (Boulton AA, Baker GB, eds), pp 69–115. Clifton, NJ: Humana.
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. *J Biol Chem* 193:265–275.
- Luber-Narod J, Rogers J (1988) Immune system associated antigens expressed by cells of the human central nervous system. *Neurosci Lett* 94:17–22.
- Matsuyama T, Kobayashi N, Yamamoto N (1991) Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? *Aids* 5:1405–1417.
- McGeer PL, Rogers J (1992) Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. *Neurology* 42:447–449.
- Merrill JE (1990) Interleukin-2 effects in the central nervous system. *Ann NY Acad Sci* 594:188–199.
- Merrill JE (1991) Bellini, Carpaccio, and receptors in the central nervous system. *J Cell Biochem* 46:191–198.
- Nieto-Sampedro M, Chandy KG (1987) Interleukin-2-like activity in injured brain. *Neurochem Res* 12:723–727.
- Nisticò G, De Sarro G (1991) Is interleukin 2 a neuromodulator in the brain? *Trends Neurosci* 14:146–150.
- Pearce LB, Buck T, Adamec E (1991) Rapid kinetics of potassium-evoked release of acetylcholine from rat brain synaptosomes: analysis by rapid superfusion. *J Neurochem* 57:636–647.
- Plata-Salamán CR (1991) Immunoregulators in the nervous system. *Neurosci Biobehav Rev* 15:185–215.
- Quirion R, Aubert I, Robitaille Y, Gauthier S, Araujo D, Chabot JG (1990) Neurochemical deficits in pathological brain aging: specificity and possible relevance for treatment strategies. *Clin Neuropharmacol* 13[Suppl 3]:73–80.
- Rabin BS, Cohen S, Ganguli R, Lysle DT, Cunnick JE (1989) Bidirectional interaction between the central nervous system and the immune system. *Crit Rev Immunol* 9:279–312.
- Raiteri M, Leardi R, Marchi M (1984) Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in rat brain. *J Pharmacol Exp Ther* 228:209–214.
- Richter JA (1976) Characteristics of acetylcholine release by superfused slices of rat brain. *J Neurochem* 26:791–797.
- Rosenberg SA (1990) Adoptive immunotherapy for cancer. *Sci Am* 262(5):62–69.
- Royston MC, Rothwell NJ, Roberts GW (1992) Alzheimer's disease: pathology to potential treatments? *Trends Pharmacol Sci* 13:131–133.
- Saris SC, Rosenberg A, Friedman RB, Rubin JT, Barba D, Oldfield EH (1988) Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. *J Neurosurg* 69:29–34.
- Scatton B, Lehmann J (1982) *N*-methyl-D-aspartate-type receptors mediate striatal ³H-acetylcholine release evoked by excitatory amino acids. *Nature* 297:422–424.
- Semba K, Fibiger HC (1989) Organization of central cholinergic systems. In: *Progress in brain research, Vol 79, Nicotinic receptors in the CNS: their role in synaptic transmission*. (Nordberg A, Fuxe K, Holmstedt B, Sundwall A), pp 37–63. Amsterdam: Elsevier.
- Seto D, Hanisch UK, Chabot JG, Quirion R (1991) Evoked efflux of endogenous acetylcholine from rat brain slices: effect of interleukin-2. *Soc Neurosci Abstr* 17:313.13.
- Sternberg EM (1989) Monokines, lymphokines, and the brain. In: *The year in immunology, Vol 5, Immunoregulatory cytokines and cell growth* (Cruse JM, Lewis RE, eds), pp 205–217. Basel: Karger.
- Tancredi V, Zona C, Velotti F, Eusebi F, Santoni A (1990) Interleukin-2 suppresses established long-term potentiation and inhibits its induction in the rat hippocampus. *Brain Res* 525:149–151.
- Vandenabeele P, Fiers W (1991) Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain? *Immunol Today* 12:217–219.
- Villemain F, Owens T, Renno T, Beaudet A (1991) Localization of mRNA for interleukin-2 (IL-2) in mouse brain by *in situ* hybridization. *Soc Neurosci Abstr* 17:475.20.
- Waldmann TA (1991) The interleukin-2 receptor. *J Biol Chem* 266:2681–2684.
- Watts RG, Wright JL, Atkinson LL, Merchant RE (1989) Histopathological and blood-brain barrier changes in rats induced by an intracerebral injection of human interleukin 2. *Neurosurgery* 25:202–208.
- Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR (1982) Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. *Science* 215:1237–1239.